Repository logo
 
Publication

Gastrointestinal disorders potentially associated with Semaglutide: an analysis from the Eudravigilance Database

2023Journal article Open access
Simple item page
dc.contributor.authorLopes, António Cabral
dc.contributor.authorRoque, Maria de Fátima dos Santos Marques
dc.contributor.authorLourenço, Olga
dc.contributor.authorHerdeiro, Maria Teresa
dc.contributor.authorMorgado, Manuel Augusto Nunes Vicente Passos
dc.date.accessioned2023-04-21T15:15:38Z
dc.date.available2023-04-21T15:15:38Z
dc.date.issued2023
dc.description.abstractBackground: Semaglutide is a Glucagon-like peptide-1 receptor agonist used in the second-line treatment of poorly controlled type 2 diabetes and can be used in monotherapy or associated with other oral antidiabetics or even insulin, increasing the effectiveness of the treatment. This work aims to analyze the profile of adverse drug reactions reported for semaglutide in Eudravigilance. Research design and methods: Data on Individual Cases Safety Reports were obtained from the database of the centralized European spontaneous reporting system Eudravigilance by accessing www. adrreports.eu. (1 December 2021). Results: It is possible to observe a high prevalence of gastrointestinal disorders (N = 3502, 53.2%). The most severe reported cases were primarily gastrointestinal disorders, metabolic, and nutritional dis orders, eye disorders, renal and urinary disorders and cardiac disorders, with an evident higher prevalence of adverse gastrointestinal events both in oral and injectable dosage form (N = 133, 50.0% vs N = 588, 47.2%, respectively). Through a comparative analysis, semaglutide had a greater number of reported gastrointestinal adverse events compared to sitagliptin and empaglifozin (p < 0.00001). Conclusions: Semaglutide has a good safety profile, however the definition of subgroups within the type 2 diabetes population who are particularly prone to develop serious adverse event when treated with GLP-1 RAs is crucial.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationAntónio Cabral Lopes, Fátima Roque, Olga Lourenço, Maria Teresa Herdeiro & Manuel Morgado (2023): Gastrointestinal disorders potentially associated with Semaglutide: an analysis from the Eudravigilance Database, Expert Opinion on Drug Safety, DOI: 10.1080/14740338.2023.2172159pt_PT
dc.identifier.doi10.1080/14740338.2023.2172159pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.6/13301
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.subjectSemaglutidept_PT
dc.subjectType 2 diabetespt_PT
dc.subjectAdverse drug reactionspt_PT
dc.subjectEudravigilancept_PT
dc.subjectGlucagon-like peptide-1pt_PT
dc.titleGastrointestinal disorders potentially associated with Semaglutide: an analysis from the Eudravigilance Databasept_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage7pt_PT
oaire.citation.startPage1pt_PT
oaire.citation.titleExpert Opinion on Drug Safetypt_PT
person.familyNameRoque
person.familyNameLourenço
person.familyNameFerreira Herdeiro
person.familyNameNunes Vicente Passos Morgado
person.givenNameFátima
person.givenNameOlga
person.givenNameMaria Teresa
person.givenNameManuel Augusto
person.identifierH-1713-2013
person.identifierAAG-4910-2021
person.identifier.ciencia-id451F-3E5A-A6C7
person.identifier.ciencia-id6618-1C4C-D1B7
person.identifier.ciencia-id8D10-B923-4EA8
person.identifier.ciencia-id7617-9FDC-2D9D
person.identifier.orcid0000-0003-0169-3788
person.identifier.orcid0000-0002-8401-5976
person.identifier.orcid0000-0002-0500-4049
person.identifier.orcid0000-0003-2112-2835
person.identifier.scopus-author-id57192101077
person.identifier.scopus-author-id8843360000
person.identifier.scopus-author-id55955252600
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication78bf0509-53e4-4437-98ea-d57aed8f9e74
relation.isAuthorOfPublicationc890c74a-abc1-4910-aa70-f0da7b4ad902
relation.isAuthorOfPublication6a3dda84-f5fc-445f-8c1c-49cb383df8bd
relation.isAuthorOfPublication7c614887-225f-44d4-b467-3cc34e44a98b
relation.isAuthorOfPublication.latestForDiscovery6a3dda84-f5fc-445f-8c1c-49cb383df8bd

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
2023_Lopes AC_ExpOpinDrugSaf.pdf
Size:
935.1 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ICI - CICS | Documentos por Auto-Depósito
FCS - DCM | Documentos por Auto-Depósito